China Resources Sanjiu Medical & Pharmaceutical Stock Forecast for 2023 - 2025 - 2030
Updated on 05/03/2024
China Resources Sanjiu Medical & Pharmaceutical Stock Forecast and Price Target
The average price target of ¥68.14 for China Resources Sanjiu Medical & Pharmaceutical's stock set by distinguished analysts in recent weeks would represent a potential upside of approximately 13.62% from the last closing price in May, 2024 if reached by the end of the year. This potential increase is based on a high estimate of ¥82.25 and a low estimate of ¥55.00. If you are interested in 000999 stock, you should also look at its competitors.
13.62% Upside
China Resources Sanjiu Medical & Pharmaceutical Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, China Resources Sanjiu Medical & Pharmaceutical's Price has seen a drop from ¥29.63 to ¥0.00 – a 100.00% decrease. The next year looks promising for China Resources Sanjiu Medical & Pharmaceutical, with analysts predicting Fair Value of ¥75.83 – an increase of 100.00%. Over the next seven years, experts anticipate that China Resources Sanjiu Medical & Pharmaceutical's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600276 Stock Forecast | Jiangsu Hengrui Medicine | Buy |
15
|
¥46.16 | Buy/Sell | ¥56.49 | 16.98% |
| 000538 Stock Forecast | Yunnan Baiyao Group Co.,Ltd | Outperform |
18
|
¥57.25 | Buy/Sell | ¥65.39 | 11.79% |
| 601607 Stock Forecast | Shanghai Pharmaceuticals Holdi... | Outperform |
18
|
¥17.92 | Buy/Sell | ¥20.67 | 22.77% |
| 600196 Stock Forecast | Shanghai Fosun Pharmaceutical ... | Outperform |
16
|
¥23.67 | Buy/Sell | ¥33.57 | 20.83% |
| 874 Stock Forecast | Guangzhou Baiyunshan Pharmaceu... | Outperform |
16
|
HK$21.90 | Buy/Sell | HK$24.33 | 4.34% |
China Resources Sanjiu Medical & Pharmaceutical Revenue Forecast for 2023 - 2025 - 2030
In the last two years, China Resources Sanjiu Medical & Pharmaceutical's Revenue has grown, increasing from ¥13.64B to ¥18.08B – a growth of 32.57%. The next year looks promising for China Resources Sanjiu Medical & Pharmaceutical, with analysts predicting Revenue of ¥29.44B – an increase of 62.82%. Over the next seven years, experts anticipate that China Resources Sanjiu Medical & Pharmaceutical's Revenue will grow at a rate of 53.60%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600079 Stock Forecast | Humanwell Healthcare (Group) | Buy |
0
|
¥20.25 | Buy/Sell | ¥32.49 | -100.00% |
| 000513 Stock Forecast | Livzon Pharmaceutical Group | Outperform |
18
|
¥36.98 | Buy/Sell | ¥39.23 | 11.41% |
| 002737 Stock Forecast | Sunflower Pharmaceutical Group... | - |
18
|
¥26.52 | Buy/Sell | ¥20.00 | -100.00% |
.jpg)
China Resources Sanjiu Medical & Pharmaceutical Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, China Resources Sanjiu Medical & Pharmaceutical's Dividend per Share has grown by 100.00%, from ¥0.50 to ¥1.00. For the next year, analysts are expecting Dividend per Share to reach ¥1.31 – an increase of 31.00%. Over the next seven years, experts predict that Dividend per Share will grow by 94.81%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 600750 Stock Forecast | Jiang Zhong Pharmaceutical Co.... | - |
18
|
¥22.77 | Buy/Sell | ¥15.25 | -100.00% |
| 600812 Stock Forecast | North China Pharmaceutical Com... | - |
12
|
¥5.18 | Buy/Sell | ¥12.26 | -100.00% |
| 600664 Stock Forecast | Harbin Pharmaceutical Group | - |
11
|
¥2.80 | Buy/Sell | ¥0.00 | -100.00% |
China Resources Sanjiu Medical & Pharmaceutical EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, China Resources Sanjiu Medical & Pharmaceutical's EBITDA has grown by 42.44%, rising from ¥2.28B to ¥3.25B. For next year, analysts predict EBITDA of ¥4.96B, which would mean an increase of 52.66%. Over the next seven years, experts predict that China Resources Sanjiu Medical & Pharmaceutical's EBITDA will grow at a rate of 72.38%.
China Resources Sanjiu Medical & Pharmaceutical EBIT Forecast for 2023 - 2025 - 2030
In the last two years, China Resources Sanjiu Medical & Pharmaceutical's EBIT has grown by 47.13%, rising from ¥1.89B to ¥2.78B. For next year, analysts predict EBIT of ¥4.45B, which would mean an increase of 59.87%. Over the next seven years, experts predict that China Resources Sanjiu Medical & Pharmaceutical's EBIT will grow at a rate of 82.84%.
China Resources Sanjiu Medical & Pharmaceutical EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, China Resources Sanjiu Medical & Pharmaceutical's EPS has seen a drop from ¥1.36 to ¥0.00 – a 100.00% decrease. The next year looks promising for China Resources Sanjiu Medical & Pharmaceutical, with analysts predicting EPS of ¥3.48 – an increase of 100.00%. Over the next seven years, experts anticipate that China Resources Sanjiu Medical & Pharmaceutical's EPS will grow at a rate of 100.00%.
Site Navigation
.jpg)